

AstraZeneca will utilize the newly launched Proteome-SEQ™ service from Biognosys

Proteome-SEQ™ standardized discovery service enables precise quantification of large proteomes across multiple samples

November 21, 2014 – Zurich-Schlieren (CH) – Biognosys AG, a Swiss Proteomics Company, announced today a collaboration project with AstraZeneca where it will utilize the recently launched [Proteome-SEQ™](#) service. This is another addition to a growing list of leading pharmaceutical companies using the next-generation proteomics technology of Biognosys.

Biognosys' [Proteome-SEQ™](#) is a comprehensive standardized discovery service for precise quantification of 1000s of proteins in parallel across multiple samples. The service addresses research questions where identification of specific protein expression differences against the backdrop of the whole proteome is important. Examples for applications are drug target discovery and biomarker development. Proteome-SEQ™ is optimized for different sample types including human tissues and is based on the [Hyper Reaction Monitoring \(HRM\) technology](#).

[HRM-MS™](#) is a next-generation mass spectrometric technology developed by Biognosys that provides reproducible and accurate quantification of 1000s of proteins in a single instrument run and in many aspects resembles next-gen sequencing in the RNA or DNA field. HRM outperforms any other proteomics technique for quantification of large number of proteins and does not require time consuming method development which is a limiting factor with classical affinity based approaches. HRM is based on data-independent acquisition (DIA or SWATH) which collects all detectable ion signals in a single instrument run. These ion maps are then queried with Biognosys powerful signal processing software [Spectronaut™](#) using pre-developed reference assay libraries. Biognosys uses a patent protected method for high-content and high-quality library generation that results in superior specificity and sensitivity compared to public assay repositories.

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

Contact: info@biognosys.ch, www.biognosys.ch